Journal Browser
Volume | Year
News and Announcements
View All

Molecular Subtype Profiling of Urothelial Carcinoma

Journal: Bladder
Submission deadline: 26 November 2024
Special Issue Editors
Tianxin Lin
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
Chong Chen
State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
Special Issue Information

Introduction of the Molecular Subtype Profiling of Urothelial Carcinoma Special Issue

     Bladder: Molecular Subtype Profiling of Urothelial Carcinoma may include: investigations on the molecular events/mechanisms underlying urothelial carcinoma that typically starts in the urothelial cells lining the urinary tract, including, the bladder, ureters, and renal pelvis. In this issue, areas of interest include (but not limited to) molecular exploration of urothelial carcinoma by employing multiomic strategies such as, genomic, transcriptomic, epigenomic, proteomic, metabolomic techniques. Emphasis is placed on molecular subtyping in different ethnic and geographic populations, and work designed to translate the molecularly defined subtypes into better patient stratification and personalized management of urothelial malignancies.

Guest Editors-in-Chief Profile

Tianxin Lin

     Dr. Tianxin Lin is a distinguished professor at Sun Yat-sen University. He is currently the President of The Fifth Affiliated Hospital of Sun Yat-sen University, the Vice President of Sun Yat-sen Memorial Hospital, the Director of the Hospital Management Department, the Deputy Director of the Health Science Center, and the Assistant Principal of Sun Yat-sen University. Prof. Lin is a recipient of National Science Fund for Distinguished Young Scholars, the Chief Scientist of National Key Research and Development Programs, and is now on the National Plan for the Special Support for Top-notch Talents. He is also serving as a standing member and secretary general of the Chinese Urological Association, the Vice President of Chinese Urological Doctor Association, and the Chairman of the Guangdong Urological Association. Prof. Lin has been working in the field of the precise diagnosis and treatment, basic research and translational medicine of urological cancer, especially bladder cancer. As the first author (including co-first) and corresponding author (including co-corresponding), Prof. Lin published over 170 papers in a wider array of prestigious journals, including CellScienceLancet OncologyCancer CellEuropean Urology, and Nature Biomedical Engineering, etc. For his outstanding accomplishments in the field of bladder cancer, Prof. Lin was awarded the National Award for Excellence in Innovation, the Ding Ying Science and Technology Award in Guangdong Province, the First Prize of Guangdong Science and Technology Progress Award, and the Wu Jieping Urological Surgery Medical Award, among others.

Chong Chen

     Dr. Chong Chen is a professor in Sichuan University. Dr. Chen graduated from Peking University and University of Michigan-Ann Arbor and earned his BS and PhD degrees, respectively. After completing his postdoctoral program in Scott Lowe’s laboratory in Cold Spring Harbor Laboratory and Memorial Sloan Kettering Cancer Center, he joined the State Key Laboratory of Biotherapy, West China Hospital, Sichuan University in 2014. His research has been focusing on the molecular mechanisms driving cancer evolution. His laboratory has established a series of novel animal models of bladder, lung, gastric cancers, and other malignancies by using genetically-engineered premalignant organoids. They have identified multiple new tumor suppressors, including KMT2C, PHF23, and ALOX15B. They found a novel type of lineage plasticity, termed "semi-squamatization", a feature underlying acquired chemoresistance, and proposed a differentiation therapy for bladder cancer. Their work has been published in Nature, Nature Cancer, Cancer Cell, and Cancer Discovery. Dr. Chen received the 2022 WuXi AppTec Life Chemistry Research Award.


Accepted types of manuscripts:

1. Research review: An in-depthsumming upof representative research results in the field over the last 5 to 10 years and their implications, with an overall review of the status quo and future trends of the relevant field. The review should be based on or directly related to the work or field the authors are engaged in.

2. Researchpapers: The original research paper should cover the latest scientific research results, which are innovative and of theoretical and practical value, such as studies regarding basic research and core technological research in the field.

3. Mini reviews: Such reviews shouldoffer a brief and focused summary of recent insights or advances in genomics and precision medicine.

4. Perspectives: Expert views and opinions ontheissues important to genomics or precision medicine.

5. Research highlights: These include short commentaries on one or more recently published journal articles that reported novel and significant findings. Research highlights should be commissioned from leading experts in the field of genomics and precision medicine.


How to submit your paper:

Author registration and submission: Please submit your paper along with a cover letter including the special issue title. Your paper will undergo a fair peer review and be published immediately after acceptance and will be available to an international audience.

Urothelial carcinoma; Bladder; Urinary; Ureters; Renal pelvis; Genomic; Transcriptomic; Epigenomic; Proteomic
Back to top
Bladder, Electronic ISSN: 2327-2120 Print ISSN: TBA, Published by POL Scientific